

2018-03

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

Perez-Gracia, JL

<http://hdl.handle.net/10026.1/10983>

10.1016/j.eururo.2017.11.023

European Urology

Elsevier

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

1 **Atezolizumab in Platinum-Treated Locally Advanced or Metastatic**
2 **Urothelial Carcinoma: Outcomes by Prior Therapy**

3

4 Jose Luis Perez-Gracia, MD^{a,*}, Yohann Loriot, MD, ^b, Jonathan E. Rosenberg, MD^c,
5 Thomas Powles, MD^d, Andrea Necchi, MD^e, Syed A. Hussain, MD^f, Rafael Morales,
6 MD^g, Margitta M. Retz, MD^h, Günter Niegisch, MDⁱ, Ignacio Durán, MD^j, Christine
7 Théodore, MD^k, Enrique Grande, MD,^l Xiaodong Shen, PhD^m, Jingjing Wang, PhD^m,
8 Christina L. Derleth, MD^m, Michiel S. van der Heijden, MDⁿ

9 ^aClínica Universidad de Navarra, Pamplona, Spain; ^bGustave Roussy, Villejuif, France;
10 ^cMemorial Sloan Kettering Cancer Center, New York, NY, USA; ^dBarts Cancer Institute,
11 Queen Mary University of London, London, UK; ^eFondazione IRCCS, Istituto Nazionale
12 dei Tumori, Milan, Italy; ^fUniversity of Liverpool, Clatterbridge Cancer Centre NHS
13 Foundation Trust, Liverpool, UK; ^gVall d'Hebron Institute of Oncology, Vall d'Hebron
14 University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; ^hUrologische
15 Klinik und Poliklinik, Technische Universität München, Munich, Germany; ⁱDepartment
16 of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf,
17 Germany; ^jInstituto de Biomedicina de Sevilla, IBI/ Hospital Universitario Virgen del
18 Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; ^kDepartment of Oncology, Hôpital
19 Foch, Suresnes, France; ^lHospital Universitario Ramón y Cajal, Madrid, Spain;
20 ^mGenentech, Inc., South San Francisco, CA; ⁿNetherlands Cancer Institute, Amsterdam,
21 the Netherlands.

22

23 Word count (abstract): 300/300

24 Word count (text, not including references, tables, figures, or legends): 2413/2500

25 Keywords (3-10 suggested): urothelial carcinoma; immunotherapy; number of prior
26 regimens, atezolizumab

27

28 * Corresponding author. Department of Oncology, University Clinic of Navarra, Avda.

29 Pio XII, 36, 31008 Pamplona, Spain. Tel: +34 948 255 400 Fax: +34 948 255 500.

30 E-mail address: E-mail address: jlgracia@unav.es (J.L. Perez-Gracia).

31 **Abstract**

32 **Background:** Historically, patients with metastatic urothelial carcinoma (mUC) who
33 progress after platinum-based chemotherapy have had few treatment options and
34 uniformly poor outcomes. Atezolizumab, a programmed cell death-ligand 1 (PD-L1)–
35 directed monoclonal antibody was recently approved in the US for cisplatin-ineligible
36 and platinum-treated mUC based on the IMvigor210 trial.

37 **Objective:** To determine the efficacy and safety of atezolizumab by the number of prior
38 lines of systemic therapy in a pre-treated mUC population.

39 **Design, setting and participants:** The IMvigor210 trial was a phase 2, multicenter,
40 single-arm, two-cohort study. Enrollment of 315 patients with mUC with progression
41 during or following platinum-based therapy occurred from May-November 2014 at 70
42 international sites. Key inclusion criteria included age ≥ 18 years, CrCl ≥ 30 mL/min and
43 ECOG PS 0–1, with no maximum restriction on prior lines of therapy.

44 **Intervention:** Patients in this cohort received atezolizumab 1200 mg IV q3w until loss of
45 clinical benefit.

46 **Outcome measurements and statistical Analysis:** Key study endpoints assessed in
47 prior treatment subgroups included RECIST v1.1 ORR, median duration of response
48 (mDOR), overall survival, and adverse event (AE) rates.

49 **Results and limitations:** 310 patients were efficacy and safety evaluable. Responses
50 occurred notwithstanding the number of prior regimens; mDOR was not reached in most
51 subgroups (median follow-up, 21 mo). No consistent OS trend or major differences in
52 toxicity were observed by line of therapy.

53 **Conclusions:** In this cohort of the IMvigor210 study, the efficacy and safety of
54 atezolizumab were demonstrated regardless of the number of prior regimens,
55 suggesting that atezolizumab provides clinical benefit across multiple prior lines of
56 therapy.

57 **Patient summary:** We evaluated the impact of different lines of therapy in a clinical
58 study of atezolizumab in patients with mUC whose disease had progressed despite
59 platinum-based therapy. Results showed that atezolizumab was clinically active and
60 tolerable regardless of the number of prior treatments regimens.

61 **1. Introduction**

62 Platinum-based chemotherapy is the standard initial approach for treating metastatic
63 urothelial carcinoma (mUC) (NCCN, 2017, Bellmunt, 2014). However, effective
64 therapies for patients who progress after first-line (1L) therapy are needed, as overall
65 survival remains short (Loerher, 1992; von der Maase, 2005; Bellmunt, 2013; NCI-
66 SEER, 2017), cisplatin ineligibility presents a challenge, especially among elderly
67 patients (Galsky, 2014), and progression on platinum is typically inevitable. Clinical trials
68 using a wide variety of chemotherapies and targeted therapies have failed to
69 significantly improve clinical outcomes, leaving a lack of effective options. In Europe,
70 vinflunine is the only approved agent for the second-line (2L) treatment of mUC
71 (Bellmunt, 2009), and until recently in the United States, no approved treatments were
72 available for patients with mUC who progressed on platinum-based chemotherapy.

73

74 Atezolizumab is a humanized engineered monoclonal antibody that selectively targets
75 anti-programmed death-ligand 1 to reinvigorate and enhance anti-cancer activity
76 (Herbst, 2014; Powles 2014). Atezolizumab has demonstrated efficacy and safety in a
77 range of cancers (Herbst, 2014) and was granted US Food and Drug Administration
78 (FDA) approval in mUC for patients both in the cisplatin-ineligible and platinum-treated
79 settings (TECENTRIQ PI, 2016). The approval in platinum-treated patients was granted
80 following results from the phase 2 IMvigor210 study, which showed that among a
81 population of generally heavily pre-treated patients, atezolizumab provided durable
82 activity and tolerability in an overall population unselected for PD-L1 expression
83 (Rosenberg, 2016).

84

85 Due to the lack of treatment options for mUC, a large proportion of patients are not
86 treated with any 2L chemotherapy, and far fewer receive treatment beyond the second
87 line (Pal, 2016; Pond, 2015). Furthermore, the differential impact of prior lines of therapy
88 in patients receiving salvage chemotherapy for mUC is unclear, as patients receiving
89 later lines of therapy have historically been under-reported or excluded from clinical
90 trials. The platinum-treated cohort of the IMvigor210 study included patients who were
91 considered heavily pre-treated in the metastatic setting, providing an opportunity to
92 assess outcomes as a function of the extent of pre-treatment. Here, we describe
93 efficacy and safety outcomes in an updated analysis based on the number of systemic
94 treatments administered in the metastatic setting prior to study enrollment.

95

96 **2. Patients and Methods**

97 ***2.1. Patients, study design, and procedures***

98 The study population for this analysis included patients with mUC who were enrolled in
99 the platinum-treated cohort of the Phase II IMvigor210 trial (ClinicalTrials.gov identifier,
100 NCT02108652). Details on this two-cohort study and general patient populations have
101 been reported previously (Balar, 2017; Rosenberg, 2016). The study protocol was
102 approved by institutional review boards or independent ethics committees at
103 participating study sites. All patients provided written informed consent before entry into
104 the study, which was performed in accordance with the Declaration of Helsinki and
105 International Conference of Harmonization Good Clinical Practice guidelines.

106

107 Key eligibility criteria specific to this cohort included locally advanced or metastatic
108 urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra (herein referred to as
109 mUC), creatinine clearance ≥ 30 mL/min and Eastern Cooperative Oncology Group
110 performance status (ECOG PS) of 0–1. Patients were required to have experienced
111 disease progression during or following ≥ 1 prior platinum-based regimen for metastatic
112 disease or in the neoadjuvant or adjuvant setting if progression occurred within 12
113 months. There were no restrictions on maximum number of prior therapies. Patients
114 received atezo 1200 mg IV q3w until loss of clinical benefit as defined by the treating
115 investigator. Confirmed, objective response rates (ORRs) were assessed using
116 Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and reviewed by an
117 independent facility (BioClinica, Princeton, NJ, USA). Central evaluation of PD-L1
118 expression (HistoGeneX, Brussels, Belgium) was performed prospectively using the
119 VENTANA SP142 immunohistochemistry assay (Ventana Medical Systems, Tucson,
120 AZ, USA). Patient samples were scored as IC2/3, IC1, or IC0 based on the percentage
121 of tumor-infiltrating immune cells (IC) with PD-L1 expression: $\geq 5\%$, $\geq 1\%$ (and $< 5\%$), or
122 $< 1\%$, respectively. Safety was assessed using National Cancer Institute Common
123 Terminology Criteria for Adverse Events version 4.0.

124

125 **2.2. Treatment definitions and assessments**

126 The IMvigor210 study protocol defined atezolizumab treatment in the metastatic setting
127 as second line and above (2L+) for patients who met the above-described inclusion
128 criteria. For the current analysis, treatment definitions were assessed as follows:

129 atezolizumab treatment was considered first line (1L) when administered to patients
130 who had only received prior platinum perioperatively. Atezolizumab treatment was
131 considered 2L, third line (3L), fourth line (4L), or fifth line and beyond (5L+) for patients
132 who received 1, 2, 3, or ≥ 4 prior regimens, respectively, specific to the metastatic
133 setting (regardless of perioperative chemotherapy). The protocol-defined primary
134 analysis (Rosenberg, 2016) evaluated co-primary endpoints of ORR based on centrally
135 assessed, confirmed RECIST v1.1 and investigator-assessed immune-modified
136 RECIST (imRECIST) (Mazieres, 2016). Secondary endpoints included duration of
137 response (DOR) and progression-free survival (by both RECIST v1.1 per independent
138 review facility and imRECIST per investigator assessment, overall survival (OS) and
139 safety. In this post-hoc analysis, centrally assessed RECIST v1.1 ORR and DOR, in
140 addition to OS and adverse event frequencies were evaluated based on the number of
141 prior treatment regimens as defined above. DOR and OS were estimated using the
142 Kaplan-Meier method (Kaplan, 1958) and 95% confidence intervals (CIs) for median OS
143 used a modified Brookmeyer and Crowley method (Brookmeyer, 1982). Descriptive
144 summaries of these analyses are presented within for this single-arm study. The date of
145 data cutoff used in this analysis was July 4, 2016.

146 **3. Results**

147 **3.1 Baseline and prior treatment characteristics**

148 Overall, 310 eligible patients were included in this analysis (Table 1). The median age
149 was 66 years, the majority (78%) were male and had visceral metastases (78%). Thirty-
150 eight percent of patients had liver metastases, and 62% had an ECOG PS of 1. Fifty-six
151 patients received only perioperative chemotherapy and were considered to have
152 received atezolizumab as 1L therapy. Of 254 (82%) patients who were treated with prior
153 therapy in the metastatic setting, 39% received 1 prior line of therapy and 43% received
154 2 or more prior regimens (Table 1). Prior platinum-based treatments predominantly
155 included cisplatin (in 73% of patients), and 26% of patients received prior carboplatin.
156 Patients also received a variety of other prior therapies, most commonly chemotherapy
157 or targeted agents (data not shown).

158

159 ***3.2 Atezolizumab treatment, follow-up duration and subsequent therapies*** 160 ***administered***

161 At the time of data cutoff (July 4, 2016), the median survival follow-up was 21.0 months
162 (range, 0.2+ to 24.5) in all patients and similar across subgroups (Supplementary Table
163 1). 310 patients had received atezolizumab for a median treatment duration of 12 weeks
164 (range, 0-104), corresponding to a median of 5 doses. Exposure was slightly lower in
165 the 3L subgroup, with no consistent pattern as a function of prior lines of therapy
166 (Supplementary Table 1).

167 At data cutoff, 14% of patients remained on treatment, and 24% of patients remained on
168 study or follow-up. Eighty-one percent of patients treated with atezolizumab (251 of 310)

169 did not receive subsequent therapy, primarily due to death ($n = 181$), remaining on
170 study treatment ($n = 43$), or other reasons ($n = 27$). Subsequent non-protocol therapies
171 were reported during follow-up for 56 evaluable patients who experienced RECIST v1.1
172 PD with independent review. As with non-protocol agents received prior to
173 atezolizumab, subsequent therapies administered varied but predominantly included
174 chemotherapy, in addition to immunotherapy and targeted or other agents (data not
175 shown).

176

177 **3.3. Independent Review Facility–assessed RECIST v1.1 response rates and** 178 **duration**

179 The ORR across all patients was 16% (95% CI, 12%–20%) and ranged from 8% (95%
180 CI, 1%–25%) in the 5L+ subgroup to 25% (95% CI, 14%–38%) in the 1L subgroup.
181 Complete and partial responses (CR and PR) were observed in all subgroups based on
182 prior regimens. In addition to ORR, CR rates were also numerically higher in patients
183 without prior treatment for mUC (1L subgroup), but no consistent trend appeared among
184 previously treated patients across the different lines of therapy (Table 2).

185

186 Responses were durable across lines of therapy, with $\geq 50\%$ of responding patients
187 experiencing ongoing responses, defined by the lack of death or progressive disease
188 (PD). The median DOR was not yet reached overall and in any subgroup except in
189 patients who received only neoadjuvant or adjuvant treatment (1L subgroups), who had
190 a median DOR of 16.0 months (range, 2.9+–19.5+ months; Table 2).

191

192 **3.4 Overall survival**

193 The median overall survival for all patients was 7.9 months, with an event rate of 73%
194 (Fig. 1A). Subgroups analyses suggest that patients with fewer prior lines of therapy
195 tended to have longer median OS, 12-month and 18-month survival rates, but no
196 consistent trend was apparent (Fig. 1A and 1B). At the time of data cut-off, event rates
197 across lines of therapy were similar (Fig. 1A).

198

199 **3.5 Safety**

200 Ninety-eight percent of patients experienced an adverse event (AE) regardless of
201 attribution. When compared between treatment subgroups, individual AE frequencies
202 were consistent, with rates of 98%, 98%, 99%, 98%, and 92% in the 1L, 2L, 3L 4L and
203 5L+ settings, respectively. Seventy-one percent of patients experienced a treatment-
204 related AE, and rates were likewise generally similar regardless of the number of lines
205 of therapy (ranging from 58% in the 5L+ subgroup to 79% in the 1L group;
206 Supplementary Table 2). The incidence of Grade 3–4 treatment related AEs in all
207 patients was 18% and was similar across the different lines of therapy (ranging from
208 15% in the 3L subgroup up to 22% in the 4L group; Table 3). The most common
209 treatment-related Grade 3–4 AEs were fatigue, increased alanine aminotransferase and
210 aspartate aminotransferase each occurring in $\leq 2\%$ of all patients, with similar
211 frequencies distributed across lines of therapy. There were no reported Grade 5
212 treatment-related AEs in any group (Table 3).

213

214 **4. Discussion**

215 Critical barriers that have limited the treatment of mUC across lines of therapy include
216 the ineligibility of many patients to receive standard-of-care cisplatin (Galsky, 2011) and
217 the historic lack of major, broadly-applicable therapeutic advances that significantly
218 improve efficacy outcomes. As a function of the inadequacies of current treatment
219 options, many patients are never treated with 1L or 2L+ chemotherapy (Pal, 2015; Pal,
220 2016). Therefore, there is very limited data on the impact of previous lines of therapy on
221 outcomes of patients with mUC (Pond, 2015). The recent 2L approvals in mUC and
222 paradigm-shifting advances of cancer immunotherapy will require more studies to
223 determine best treatment practices and appropriate treatment patterns and sequencing.

224

225 The phase 2 IMvigor210 study showed atezolizumab to be effective and safe among
226 patients with mUC who progressed during or after platinum-based chemotherapy for
227 mUC (Rosenberg, 2016). The study included heavily pre-treated patients, with 43% of
228 patients treated with ≥ 2 regimens, mostly chemotherapy, prior to starting atezolizumab.
229 Here, we report that the clinical benefit of atezolizumab extends to patients
230 independently of the number of previous lines of therapy. Almost all patients in the
231 current study who were considered to have received 1L atezolizumab were required to
232 have experienced disease progression within 12 months of perioperative platinum-
233 based chemotherapy (except for two patients who were enrolled due to protocol
234 violation, see Table 2). In this subgroup without prior treatment for mUC, ORR and
235 landmark OS rates appeared numerically higher in patients, with numerically longer
236 mOS as well. However, no consistent trend in efficacy based on number of regimens
237 was observed. This pattern is in agreement with data from a phase 2 study of 265

238 previously treated patients with mUC who received the checkpoint inhibitor nivolumab,
239 also recently granted FDA approval; ORR was generally similar in patients with either 0,
240 1, 2 or 3 prior regimens for mUC, although other outcomes were not reported for these
241 subgroups (Sharma, 2017).

242

243 The possible impacts of prior treatments on toxicities experienced by patients treated
244 with immunotherapies in later lines of therapy are not well characterized, and the
245 potential for increased toxicity may depend on a number of factors, including
246 comorbidities, age, and/or prior treatment effects. In our study, atezolizumab was well
247 tolerated, with no major differences in the rates of AEs. Safety was generally consistent
248 across lines of therapy, and more heavily pre-treated patients did not appear to have
249 increased toxicity. Importantly, heavily pre-treated patients had similar grade 3-4
250 treatment-related AEs frequencies as compared with those treated in earlier settings.
251 Overall, the most common such toxicity was grade 3–4 fatigue that occurred in $\leq 3\%$ of
252 patients in all subgroups independent of prior treatments. Overall, these results suggest
253 that the toxicity profile was generally consistent regardless of number of prior regimens.

254

255 To our knowledge, this study represents the largest clinical assessment of the impacts
256 of pre-treatment on checkpoint inhibitor efficacy outcomes in mUC—and the only such
257 analysis of safety—to date. Still, as a post-hoc analysis, this study was not designed to
258 prospectively control for the numbers of patients enrolled in each prior regimen
259 subgroup, or the clinical or treatment characteristics of each group, some of which
260 contain few patients (e.g. $n = 26$ for 5L+ subgroup). Of note, exposure was consistent,

261 and median follow-up duration concordant across these groups. Based on the single-
262 arm nature of the study, we used descriptive statistics to evaluate efficacy and safety
263 outcomes, since the interpretation of formal statistical tests would otherwise be
264 confounded by the lack of a control arm and thus unable to distinguish between
265 predictive treatment effects and prognostics effect across lines of therapy. Previous
266 analyses have identified clinical and prior treatment factors that may be prognostic for
267 survival outcomes in the 1L or 2L+ settings (Bajorin, 1999; Bellmunt, 2013; Sonpavde,
268 2013). Pond et al. (2015) conducted a large ($n = 710$) pooled analysis of 10 prospective
269 phase II trials of salvage systemic chemotherapy, biologic agent therapy, or both, and
270 evaluated the impact of prior lines of therapy on the prognosis of patients with advanced
271 UC. Across studies, approximately 16% ($n = 111$), 4% ($n = 29$) and 2% ($n = 12$) of
272 patients received 2, 3 or ≥ 4 lines of prior therapy, respectively, and the number of prior
273 lines was not found to be significantly associated with OS in either univariate or
274 multivariate analyses, although perioperative chemo (given to 39%, $n = 277$) was
275 favorably associated with OS in univariate analyses (Pond, 2015). Collectively, these
276 data suggest that in patients who progress despite platinum-based therapy,
277 atezolizumab may provide clinical benefit more broadly across multiple lines of therapy.

278

279 **Conclusions**

280 This analysis evaluated the impact of prior lines of therapy among generally heavily pre-
281 treated patients with mUC who progressed during or after platinum-based
282 chemotherapy and were enrolled in the IMvigor210 study. Results showed that
283 treatment with atezolizumab conferred durable, clinically meaningful benefit

284 notwithstanding the number of prior lines of therapy with no observed differences in
285 safety.

286

287 **Author contributions:** Jose Luis Perez-Gracia had full access to all the data in the
288 study and takes responsibility for the integrity of the data and the accuracy of the data
289 analysis.

290 *Study concept and design:* TBC.

291 *Acquisition of data:* TBC.

292 *Analysis and interpretation of data:* All authors/TBC.

293 *Drafting of the manuscript:* TBC.

294 *Critical revision of the manuscript for important intellectual content:* All authors/TBC.

295 *Statistical analysis:* Wang.

296 *Obtaining funding:* TBC.

297 *Administrative, technical, or material support:* TBC.

298 *Supervision:* TBC.

299 *Other:* None/TBC.

300

301 **Financial disclosures:** TBC

302 **Funding/Support and role of the sponsor:** TBC.

303 **Acknowledgments:** We thank Abidoye Oyewale, Shi Li, and Yan Zheng for their
304 contributions to the study. Medical writing assistance for this poster was provided by
305 Eric Berlin, MD, of Health Interactions and funded by F. Hoffmann-La Roche, Ltd.

306

307 **Appendix A. Supplementary data**

308 Supplementary data associated with this article can be found in the online version.

309 **References**

- 310 [1] Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in
311 cisplatin-ineligible patients with locally advanced and metastatic urothelial
312 carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet*. 2017;389(10064):67-
313 76.
- 314 [2] Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic
315 transitional-cell carcinoma and prognostic factors predicting outcome of therapy. *J*
316 *Clin Oncol*. 1999; 17(10):3173-3181.
- 317 [3] Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best
318 supportive care compared with best supportive care alone after a platinum-
319 containing regimen in patients with advanced transitional cell carcinoma of the
320 urothelial tract. *J Clin Oncol*. 2009;27(27):4454-4461.
- 321 [4] Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with
322 advanced transitional cell carcinoma of the urothelial tract experiencing treatment
323 failure with platinum-containing regimens. *J Clin Oncol*. 2010;28(11):1850-1855.
- 324 [5] Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a
325 randomized phase III trial of vinflunine plus best supportive care versus best
326 supportive care alone in advanced urothelial carcinoma patients after failure of
327 platinum-based chemotherapy. *Ann Oncol*. 2013;24:1466-1472.
- 328 [6] Bellmunt J, Orsola A, Leow JJ, et al. Bladder cancer: ESMO Practice Guidelines
329 for diagnosis, treatment and follow-up. *Ann Oncol*. 2014;25 Suppl 3:iii40-48.
- 330 [7] Brookmeyer R, Crowley J. A confidence interval for the median survival time.
331 *Biometrics* 1982; 38: 29–41.

- 332 [8] Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic
333 urothelial cancer "unfit" for Cisplatin-based chemotherapy. *J Clin Oncol.*
334 2011;29:2432-2438.
- 335 [9] Galsky MD, Krege S, Lin CC, et al. Cisplatin-based combination chemotherapy in
336 septuagenarians with metastatic urothelial cancer. *Urol Oncol.* 2014;32:30.e15-21.
- 337 [10] Herbst RS, Soria JC, Kowanzetz M, et al. Predictive correlates of response to the
338 anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* 2014; 515: 563–67.
- 339 [11] Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *Am*
340 *Stat Assoc* 1958; 53:457-481
- 341 [12] Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin
342 alone or in combination with methotrexate, vinblastine, and doxorubicin in patients
343 with metastatic urothelial carcinoma: a cooperative group study. *J Clin Oncol.*
344 1992;10:1066-1073.
- 345 [13] Mazieres J, Fehrenbacher L, Rittmeyer A, et al. Non-classical Response Measured
346 by Immune-Modified RECIST and Post-Progression Treatment Effects if
347 Atezolizumab in 2L/3L NSCLC: Results From the Randomized Phase II Study
348 POPLAR. Presented at American Society of Clinical Oncology 2016 (ASCO 2016)
349 June 3 – 7, 2016, Chicago, IL, USA
- 350 [14] NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. V2.2016.
- 351 [15] National Cancer Institute Surveillance, Epidemiology, and End Results Program.
352 SEER cancer statistics factsheets: Bladder cancer.
353 <http://seer.cancer.gov/statfacts/html/urinb.html> (accessed Apr 28, 2017).

- 354 [16] Pal SK, Lin YI, Yuh B, et al. Conditional survival in de novo metastatic urothelial
355 carcinoma. *PLoS One*. 2015;10:e0136622.
- 356 [17] Pal SK, Galsky MD, Lin SW, et al. Second-Line Metastatic Urothelial Carcinoma
357 Treatment and Survival in Real-World Patients in the United States. Presented at
358 European Society for Medical Oncology 2016 (ESMO 2016) – October 7-11, 2016,
359 Copenhagen, Denmark.
- 360 [18] Pond GR, Bellmunt J, Rosenberg JE, et al. Impact of the number of prior lines of
361 therapy and prior perioperative chemotherapy in patients receiving salvage therapy
362 for advanced urothelial carcinoma: implications for trial design. *Clin Genitourin*
363 *Cancer*. 2015;13(1):71-79.
- 364 [19] Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to
365 clinical activity in metastatic bladder cancer. *Nature* 2014; 515: 558–62.
- 366 [20] Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with
367 locally advanced and metastatic urothelial carcinoma who have progressed
368 following treatment with platinum-based chemotherapy: a single-arm, multicentre,
369 phase 2 trial. *Lancet* 2016;387(10031):1909-1920.
- 370 [21] Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial
371 carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm,
372 phase 2 trial. *Lancet Oncol*. 2017;18(3):312-322.
- 373 [22] Sonpavde G, Pond GR, Fougeray R, et al. Time from prior chemotherapy
374 enhances prognostic risk grouping in the second-line setting of advanced urothelial
375 carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. *Eur Urol*.
376 2013 Apr;63(4):717-23.

- 377 [23] TECENTRIQ (atezolizumab) [package insert]. South San Francisco, CA:
378 Genentech, Inc; 2016.
- 379 [24] von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a
380 randomized trial comparing gemcitabine plus cisplatin, with methotrexate,
381 vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J Clin Oncol.*
382 2005;23:4602-4608.

383 **Figure Legends**

384 **Fig. 1 – Overall survival (OS) by prior regimen: (A) Median OS and landmark OS**
385 **rates and (b) Kaplan-Meier curves. Data cutoff date: July 4, 2016.**

386 1L = first line; 2L = second line; 3L = third line; 4L = fourth line; 5L: fifth line; OS =
387 overall survival.

388 **Tables**389 **Table 1 – Key clinical and prior treatment characteristics at baseline**

Baseline Characteristic	All Patients (N = 310)
Median age, yr (range)	66 (32–91)
Sex, n (%)	
Male	241 (77.7)
Female	69 (22.3)
ECOG PS, n (%)	
0	117 (37.7)
1	193 (62.3)
Primary tumor site, n (%)	
Bladder	233 (75.2)
Non-bladder	77 (25.8)
Metastatic site(s), n (%)	
Visceral	243 (78.4)
Liver	96 (31.0)
PD-L1 status, n (%) ^a	
IC2/3	100 (32.3)
IC1	107 (34.5)
IC0	103 (33.2)
Time from prior chemotherapy, n (%) ^b	
≤ 3 mo	121 (39.0)
Prior platinum received, n (%) ^b	
Cisplatin	226 (72.9)
Carboplatin	81 (26.1)
Other platinum	3 (1.0)
Prior systemic regimens for metastatic disease, n (%)	
0 (1L) ^c	56 (18.1)
1 (2L)	121 (39.0)
2 (3L)	66 (21.3)
3 (4L)	41 (13.2)
≥4 (5L+)	26 (8.4)

ECOG PS = Eastern Cooperative Oncology Group Performance Status;
IC = tumor-infiltrating immune cell.
^a PD-L1 status on IC.
^b In all treatment settings.
^c Perioperative treatment setting only.
Data cutoff date: July 4, 2016.

391

392 **Table 2 – Response rates and durations by prior regimen**

	Prior regimens for mUC					All Patients (N = 310) ^a
	0 (1L) (n = 56) ^f	1 (2L) (n = 121)	2 (3L) (n = 66)	3 (4L) (n = 41)	≥4 (5L+) (n = 26)	
ORR, n(%) ^a	14 (25.0)	16 (13.2)	10 (15.2)	7 (17.1)	2 (7.7)	49 (15.8)
ORR 95% confidence interval	14.4–38.4	7.8–20.6	7.5–26.1	7.2–32.1	1.0–25.1	11.9–20.4
Response status, n (%) ^b						
CR	6 (10.7)	6 (5.0)	4 (6.1)	2 (4.9)	1 (3.8)	19 (6.1)
PR	8 (14.3)	10 (8.3)	6 (9.1)	5 (12.2)	1 (3.8)	30 (9.7)
SD	10 (17.9)	24 (19.8)	13 (19.7)	7 (17.1)	4 (15.4)	58 (18.7)
PD	26 (46.4)	63 (52.1)	32 (48.5)	20 (48.8)	16 (61.5)	157 (50.6)
Ongoing responses, n (%) ^c	7 (50.0)	9 (56.3)	8 (80.0)	6 (85.7)	2 (100.0)	32 (65.3)
Median DOR, mo ^d	16.0	not reached	not reached	not reached	not reached	not reached
DOR range ^e	2.9+–19.5+	4.2–19.4+	4.7–21.8+	2.1+–19.6+	17.6+– 22.6+	2.1+–22.6+

1L = first line; 2L = second line; 3L = third line; 4L = fourth line; 5L = fifth line; CR = complete response; DOR = duration of response; ORR = objective response rate; PR = partial response; PD = progressive disease; RECIST = Response Evaluation Criteria In Solid Tumors; SD = stable disease.

^a Objective-response evaluable population includes 46 patients with missing/unevaluable responses.

^b Responses were assessed using RECIST v1.1 per independent review.

^c No death or PD at data cutoff.

^d In patients with an objective response.

^e Censored values are indicated with a plus symbol.

^f Neoadjuvant or adjuvant chemotherapy only in patients with disease progression within 12 mo of chemotherapy (n = 54) or those with progression at or after 12 mo of chemotherapy (n = 2; enrolled into cohort 2 due to protocol violation).

Data cutoff date: July 4, 2016.

393

394 **Table 3. Grade 3–4 treatment-related adverse events (AEs) by prior regimen**

AE, n (%) ^a	Prior regimens for mUC					All Patients (N = 310)
	0 (1L) (n = 56)	1 (2L) (n = 121)	2 (3L) (n = 66)	3 (4L) (n = 41)	≥4 (5L+) (n = 26)	
All Grade 3–4 AEs	13 (23%)	19 (16%)	10 (15%)	9 (22%)	5 (19%)	56 (18%)
Fatigue	0 (0%)	2 (2%)	2 (3%)	1 (2%)	0 (0%)	5 (2%)
AST increased	1 (2%)	1 (1%)	1 (2%)	1 (2%)	0 (0%)	4 (1%)
ALT increased	1 (2%)	0 (0%)	2 (3%)	1 (2%)	0 (0%)	4 (1%)
Pneumonitis	2 (4%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)	3 (1%)
Lymphocyte count decreased	1 (2%)	1 (1%)	1 (2%)	0 (0%)	0 (0%)	3 (1%)
Hypertension	1 (2%)	1 (1%)	1 (2%)	0 (0%)	0 (0%)	3 (1%)
Colitis	1 (2%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	2 (1%)
Decreased appetite	0 (0%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)
Arthralgia	0 (0%)	0 (0%)	0 (0%)	1 (2%)	1 (4%)	2 (1%)
Dyspnea	0 (0%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)
Anemia	0 (0%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)
Hypotension	1 (2%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)	2 (1%)

1L = first line; 2L = second line; 3L = third line; 4L = fourth line; 5L = fifth line; AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase.
^a Occurring in ≥ 2 patients [1%] overall). Multiple occurrences of the same event were counted once at highest grade.
 Data cutoff date: July 4, 1016.

395

396 **Figures**


397 **Figure 1 – Overall survival by prior regimen**

398 **(A) Median and landmark overall survival**

	Prior Regimens for mUC					All Patients (N = 310)
	0 (1L) (n = 56)	1 (2L) (n = 121)	2 (3L) (n = 66)	3 (4L) (n = 41)	≥4 (5L+) (n = 26)	
Median OS, mo	9.6	9.0	5.9	6.4	7.4	7.9
95% CI	5.9–15.8	7.3–11.3	3.3–8.7	3.8–10.2	4.6–11.2	6.7–9.3
12-mo OS rate, %	45	38	34	33	28	37
95% CI	32–58	29–47	23–46	18–47	10–46	31–42
18-mo OS rate, %	34	26	28	28	20	27
95% CI	21–46	18–34	17–39	14–42	4–36	22–32
OS events, n (%)	39 (70)	89 (74)	47 (71)	31 (76)	20 (77)	226 (73)

399

400 **(B) Kaplan-Meier overall survival curves**



401

402 **Appendix A. Supplementary data**

403 **Supplementary tables**

404 **Supplementary Table 1 – Exposure and follow-up durations by prior regimen**

	Prior Regimens for mUC					All Patients (N = 310)
	0 (1L) (n = 56)	1 (2L) (n = 121)	2 (3L) (n = 66)	3 (4L) (n = 41)	≥4 (5L+) (n = 26)	
Median treatment duration, wk	15.5	12.1	7.3	12.3	11.4	12.3
Range	0–100	0–104	0–101	0–100	0–100	0–104
Median number of doses, n	6.0	5.0	3.0	5.0	4.5	5.0
Range	1–34	1–35	1–34	1–34	1–32	1–35
Median follow-up duration, mo	20.7	20.7	21.3	22.1	21.8	21.0
Range	0.6+–23.2	0.5+–24.5	0.2+–23.4	1.2+–23.1	0.5+–24.2	0.2+–24.5
1L = first line; 2L = second line; 3L = third line; 4L = fourth line; 5L = fifth line.						
Data cutoff date: July 4, 2016.						

405

406 **Supplementary Table 2 – All grade treatment-related adverse events (AEs) by**
 407 **prior regimen**

AE, n (%) ^a	Prior Regimens for mUC					All Patients (N = 310)
	0 (1L) (n = 56)	1 (2L) (n = 121)	2 (3L) (n = 66)	3 (4L) (n = 41)	≥4 (5L+) (n = 26)	
All Grade AEs	44 (79%)	91 (75%)	43 (65%)	27 (66%)	15 (58%)	220 (71%)
Fatigue	19 (34)	38 (31)	23 (35)	11 (27)	4 (15)	95 (31)
Nausea	11 (20)	14 (12)	12 (18)	3 (7)	2 (8)	42 (14)
Pruritus	9 (16)	15 (12)	7 (11)	5 (12)	1 (4)	37 (12)
Decreased appetite	4 (7)	15 (12)	9 (14)	4 (10)	3 (12)	35 (11)
Pyrexia	6 (11)	15 (12)	5 (8)	2 (5)	0 (0)	28 (9)
Diarrhea	5 (9)	10 (8)	6 (9)	4 (10)	1 (4)	26 (8)
Vomiting	1 (2)	7 (6)	8 (12)	2 (5)	2 (8)	20 (7)

1L = first line; 2L = second line; 3L = third line; 4L = fourth line; 5L = fifth line; AE = adverse event.

^a Occurring in ≥ 10% of patients in any subgroup. Multiple occurrences of the same event were counted once at highest grade.

Data cutoff date: July 4, 2016.

408